Vertex Pharmaceuticals remains on hold with a $494 price target from Stifel analysts after discussions about its chronic pain ...

Vertex Pharmaceuticals is making waves with its new pain treatment, Journavx, which is experiencing a prescription growth ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF).

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the ...